Dickkopf-1 overexpression in vitro nominates candidate blood biomarkers relating to Alzheimer’s disease pathology

Manuscript Number: 

20-0208R3

Author(s): 
Daniel Alcolea, Nicholas J. Ashton, Alison L. Baird, Frederik Barkhof, Lars Bertram, Kaj Blennow, Olivier Blin, Régis Bordet, Isabelle Bos, Noel J. Buckley, Antonio Cuadrado, Ellen De Roeck, Valerija Dobricic, Richard Dobson, Sebastiaan Engelborghs, Andre Franke, Yvonne Freund-Levi, Ruth Frikke-Schmidt, Giovanni B. Frisoni, Lutz Frölich, Silvy Gabel, Shengjun Hong, Abdul Hye, Peter Johannsen, Petronella Kettunen, Steven J. Kiddle, Richard Killick, Fabian Kilpert, Iwona Kloszewska, Cristina Legido-Quigley, Benjamine Liu, Alberto Lleó, Simon Lovestone, Pablo Martínez-Lage, Patrizia Mecocci, Karen Meersmans, José-Luis Molinuevo, Angharad R. Morgan, B. Paul Morgan, Alejo Nevado-Holgado, Sune Fallgaard Nielsen, Børge Grønne Nordestgaard, Gwendoline Peyratout, Julius Popp, Lorena Rami, Katrine Laura Rasmussen, Elena M. Ribe, Jill Richardson, Martina Sattlecker, Philip Scheltens, Liu Shi, Kristel Sleegers, Hilkka Soininen, Johannes Streffer, Mikel Tainta, Charlotte E. Teunissen, Magda Tsolaki, Rik Vandenberghe, Bruno Vellas, Frans Verhey, Pieter Jelle Visser, Stephanie J.B. Vos, Anders Wallin, Sarah Westwood, Laura M. Winchester, Henrik Zetterberg, Mara ten Kate

Disclosures

Daniel Alcolea

  • Nothing to Disclose

Nicholas J. Ashton

  • Nothing to Disclose

Alison L. Baird

  • Nothing to Disclose

Frederik Barkhof

  • Consulting Fees:
    SC or IDMC member for Biogen, Roche, Merck, Bayer

Lars Bertram

  • Nothing to Disclose

Kaj Blennow

  • Nothing to Disclose

Olivier Blin

  • Nothing to Disclose

Régis Bordet

  • Nothing to Disclose

Isabelle Bos

  • Nothing to Disclose

Noel J. Buckley

  • Nothing to Disclose

Antonio Cuadrado

  • Nothing to Disclose

Ellen De Roeck

  • Nothing to Disclose

Valerija Dobricic

  • Nothing to Disclose

Richard Dobson

  • Nothing to Disclose

Sebastiaan Engelborghs

  • Consulting Fees:
    Novartis, Biogen, Eisiai, Nutricia / Danone
    Grants
    • Agency: 
      Janssen Pharmaceutica and ADx Neurosciences
      Dates: 
      2015-2021

Andre Franke

  • Nothing to Disclose

Yvonne Freund-Levi

  • Nothing to Disclose

Ruth Frikke-Schmidt

  • Nothing to Disclose

Giovanni B. Frisoni

  • Nothing to Disclose

Lutz Frölich

  • Nothing to Disclose

Silvy Gabel

  • Nothing to Disclose

Shengjun Hong

  • Nothing to Disclose

Abdul Hye

  • Nothing to Disclose

Peter Johannsen

  • Nothing to Disclose

Petronella Kettunen

  • Nothing to Disclose

Steven J. Kiddle

  • Consulting Fees:
    SJK has performed consultancy for DIADEM ltd and served on an advisory board for Roche Diagnostics, both in the area of blood tests for Alzheimer's disease but not directly related to this work. SJK performed this work before joining AstraZeneca, where my work is not related to Alzheimer's disease.

Richard Killick

  • Nothing to Disclose

Fabian Kilpert

  • Nothing to Disclose

Iwona Kloszewska

  • Nothing to Disclose

Cristina Legido-Quigley

  • Consulting Fees:
    SAB Alzheimer's fondation SAB Institut Pasteur

Benjamine Liu

  • Equity:
    I am the co-founder and minority owner of TrialSpark, a technology company in the clinical trials space.

Alberto Lleó

  • Nothing to Disclose

Simon Lovestone

  • Consulting Fees:
    In the past five years ; consultancy (single meetings) for Merck, Eisai and Optum labs
    Grants
    • Agency: 
      IMI (EMIF and EPAD) EU funding with multiple pharma companies in public private partnerships
      Dates: 
      2000-2019
    • Agency: 
      Astra Zeneca
      Dates: 
      2016-2020

Pablo Martínez-Lage

  • Consulting Fees:
    I have received honoraries for participating in Advisory boards for Roche, Biogen, Nutricia
    Lecture Fees:
    I have received honoraries for lecturing from Roche, Nutricia, Eisai

Patrizia Mecocci

  • Nothing to Disclose

Karen Meersmans

  • Nothing to Disclose

José-Luis Molinuevo

  • Nothing to Disclose

Angharad R. Morgan

  • Nothing to Disclose

B. Paul Morgan

  • Consulting Fees:
    Scientific advisory Board for RaPharma; fees variable but <£10k pa.
    Patents/Royalties
    Patents in area of complement therapeutics, held by University and not relevant to this work.
    Grants
    • Agency: 
      GlaxoSmithKline
      Dates: 
      2017-2020

Alejo Nevado-Holgado

  • Consulting Fees:
    I am a consultan in Akrivia Health (https://akriviahealth.com/)
    Equity:
    I own stock options of Akrivia Health (https://akriviahealth.com/)
    Grants
    • Agency: 
      Johnson and Johnson
      Dates: 
      2018-2022
    • Agency: 
      Ono Pharma
      Dates: 
      2018-2020

Sune Fallgaard Nielsen

  • Nothing to Disclose

Børge Grønne Nordestgaard

  • Nothing to Disclose

Gwendoline Peyratout

  • Nothing to Disclose

Julius Popp

  • Nothing to Disclose

Lorena Rami

  • Nothing to Disclose

Katrine Laura Rasmussen

  • Nothing to Disclose

Elena M. Ribe

  • Nothing to Disclose

Jill Richardson

  • Nothing to Disclose

Martina Sattlecker

  • Nothing to Disclose

Philip Scheltens

  • Nothing to Disclose

Liu Shi

  • Nothing to Disclose

Kristel Sleegers

  • Nothing to Disclose

Hilkka Soininen

  • Consulting Fees:
    Consultations fee from ACImmune, MERCK and Novo Nordisk outside this work.

Johannes Streffer

  • Sponsors:
    I have been an employee of Janssen Pharmaceutica till 2017. Since 2017, I am employee of UCB biopharm

Mikel Tainta

  • Nothing to Disclose

Mara ten Kate

  • Nothing to Disclose

Charlotte E. Teunissen

  • Consulting Fees:
    Roche: consulting fee
    Lecture Fees:
    Roche, Lecture fee

Magda Tsolaki

  • Nothing to Disclose

Rik Vandenberghe

  • Nothing to Disclose

Bruno Vellas

  • Nothing to Disclose

Frans Verhey

  • Nothing to Disclose

Pieter Jelle Visser

  • Nothing to Disclose

Stephanie J.B. Vos

  • Nothing to Disclose

Anders Wallin

  • Nothing to Disclose

Sarah Westwood

  • Nothing to Disclose

Laura M. Winchester

  • Nothing to Disclose

Henrik Zetterberg

  • Consulting Fees:
    HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx.
    Equity:
    HZ is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.
    Lecture Fees:
    HZ has given lectures in symposia sponsored by Biogen and Alzecure.